Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.

Moens A, van der Woude CJ, Julsgaard M, Humblet E, Sheridan J, Baumgart DC, Gilletta De Saint-Joseph C, Nancey S, Rahier JF, Bossuyt P, Cremer A, Dewit S, Eriksson C, Hoentjen F, Krause T, Louis E, Macken E, Milenkovic Z, Nijs J, Posen A, Van Hootegem A, Van Moerkercke W, Vermeire S, Bar-Gil Shitrit A, Ferrante M.

Aliment Pharmacol Ther. 2019 Nov 6. doi: 10.1111/apt.15539. [Epub ahead of print]

PMID:
31692017
2.

Improved high-quality colon cleansing with 1L NER1006 versus 2L polyethylene glycol + ascorbate or oral sulfate solution.

Repici A, Coron E, Sharma P, Spada C, Di Leo M, Noble CL, Gschossmann J, Bargalló García A, Baumgart DC.

Dig Liver Dis. 2019 Aug 10. pii: S1590-8658(19)30684-X. doi: 10.1016/j.dld.2019.06.026. [Epub ahead of print]

3.

Perspectives of the International Society for Cell & Gene Therapy Gastrointestinal Scientific Committee on the Intravenous Use of Mesenchymal Stromal Cells in Inflammatory Bowel Disease (PeMeGi).

Ciccocioppo R, Baumgart DC, Dos Santos CC, Galipeau J, Klersy C, Orlando G.

Cytotherapy. 2019 Aug;21(8):824-839. doi: 10.1016/j.jcyt.2019.05.003. Epub 2019 Jun 11.

PMID:
31201092
4.

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?

Baumgart DC, Misery L, Naeyaert S, Taylor PC.

Front Pharmacol. 2019 Mar 28;10:279. doi: 10.3389/fphar.2019.00279. eCollection 2019. Review.

5.

Perceived distress, personality characteristics, coping strategies and psychosocial impairments in a national German multicenter cohort of patients with Crohn's disease and ulcerative colitis.

Petruo VA, Krauss E, Kleist A, Hardt J, Hake K, Peirano J, Krause T, Ehehalt R, von Arnauld de la Perriére P, Büning J, Treml O, Krauss N, Albrecht H, Felten G, Hermannspahn U, Burkhardt U, Eisold M, Teich N, Siegmund B, Maaser C, Bokemeyer B, Baumgart DC, Neurath MF, Mudter J; German IBD Study Group (GISG) KND.

Z Gastroenterol. 2019 Apr;57(4):473-483. doi: 10.1055/a-0838-6371. Epub 2019 Apr 9.

PMID:
30965377
6.

Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype.

Sowa M, Kolenda R, Baumgart DC, Pratschke J, Papp M, Tornai T, Suchanski J, Bogdanos DP, Mytilinaiou MG, Hammermann J, Laass MW, Conrad K, Schramm C, Franke A, Roggenbuck D, Schierack P.

Front Immunol. 2018 Aug 28;9:1959. doi: 10.3389/fimmu.2018.01959. eCollection 2018.

7.

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects.

Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D, Taylor SA, Rimola J, Rieder F, Limdi JK, Laghi A, Krustiņš E, Kotze PG, Kopylov U, Katsanos K, Halligan S, Gordon H, González Lama Y, Ellul P, Eliakim R, Castiglione F, Burisch J, Borralho Nunes P, Bettenworth D, Baumgart DC, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR].

J Crohns Colitis. 2019 Mar 26;13(3):273-284. doi: 10.1093/ecco-jcc/jjy114. No abstract available.

PMID:
30137278
8.

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications.

Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, Calabrese E, Baumgart DC, Bettenworth D, Borralho Nunes P, Burisch J, Castiglione F, Eliakim R, Ellul P, González-Lama Y, Gordon H, Halligan S, Katsanos K, Kopylov U, Kotze PG, Krustinš E, Laghi A, Limdi JK, Rieder F, Rimola J, Taylor SA, Tolan D, van Rheenen P, Verstockt B, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR].

J Crohns Colitis. 2019 Feb 1;13(2):144-164. doi: 10.1093/ecco-jcc/jjy113. No abstract available.

PMID:
30137275
9.

Colon cleansing efficacy and safety with 1 L NER1006 versus sodium picosulfate with magnesium citrate: a randomized phase 3 trial.

Schreiber S, Baumgart DC, Drenth JPH, Filip RS, Clayton LB, Hylands K, Repici A, Hassan C; DAYB Study Group.

Endoscopy. 2019 Jan;51(1):73-84. doi: 10.1055/a-0639-5070. Epub 2018 Jul 19.

PMID:
30025415
10.

Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease.

Julsgaard M, Kjeldsen J, Brock B, Baumgart DC.

Aliment Pharmacol Ther. 2018 Aug;48(3):386-388. doi: 10.1111/apt.14837. No abstract available.

PMID:
29998502
11.

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis.

Mahadevan U, Dubinsky MC, Su C, Lawendy N, Jones TV, Marren A, Zhang H, Graham D, Clowse MEB, Feldman SR, Baumgart DC.

Inflamm Bowel Dis. 2018 Nov 29;24(12):2494-2500. doi: 10.1093/ibd/izy160.

12.

Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach.

Peyrin-Biroulet L, Baumgart DC, Armuzzi A, Gionchetti P, Sebastian S, Danese S, Magro F, Higgins S, Yaworksy A, Banderas B, Kachroo S.

Dig Dis. 2018;36(5):346-353. doi: 10.1159/000489845. Epub 2018 Jul 3.

PMID:
29969780
13.

Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.

Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M.

Inflamm Bowel Dis. 2018 Oct 12;24(11):2442-2451. doi: 10.1093/ibd/izy155.

PMID:
29788318
14.

US Time-Harmonic Elastography: Detection of Liver Fibrosis in Adolescents with Extreme Obesity with Nonalcoholic Fatty Liver Disease.

Hudert CA, Tzschätzsch H, Guo J, Rudolph B, Bläker H, Loddenkemper C, Luck W, Müller HP, Baumgart DC, Hamm B, Braun J, Holzhütter HG, Wiegand S, Sack I.

Radiology. 2018 Jul;288(1):99-106. doi: 10.1148/radiol.2018172928. Epub 2018 May 15.

PMID:
29762096
15.

Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis.

Dignass A, Akbar A, Baumgart DC, Bommelaer G, Bouguen G, Cadiot G, Gillessen A, Grimaud JC, Hart A, Hoque S, Makins R, Michiels C, Moreau J, Premchand P, Ramlow W, Schanz S, Subramanian S, von Tirpitz C, Bonaz B.

Scand J Gastroenterol. 2018 Apr;53(4):442-448. doi: 10.1080/00365521.2018.1447598. Epub 2018 Mar 7.

PMID:
29513111
16.

Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany - a real-world evidence analysis.

Stein J, Haas JS, Ong SH, Borchert K, Hardt T, Lechat E, Nip K, Foerster D, Braun S, Baumgart DC.

Clinicoecon Outcomes Res. 2018 Feb 5;10:93-103. doi: 10.2147/CEOR.S150900. eCollection 2018.

17.

Proceedings of the signature series event of the international society for cellular therapy: "Advancements in cellular therapies and regenerative medicine in digestive diseases," London, United Kingdom, May 3, 2017.

Ciccocioppo R, Dos Santos CC, Baumgart DC, Cangemi GC, Cardinale V, Ciacci C, De Coppi P, Haldar D, Klersy C, Nostro MC, Ott M, Piemonti L, Tomei AA, Uygun B, Vetrano S, Orlando G.

Cytotherapy. 2018 Mar;20(3):461-476. doi: 10.1016/j.jcyt.2017.12.004. Epub 2018 Feb 15.

18.

Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease.

Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Diez MC, Tagarro I, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators.

Gastroenterology. 2018 Apr;154(5):1334-1342.e4. doi: 10.1053/j.gastro.2017.12.020. Epub 2017 Dec 24.

PMID:
29277560
19.

Immunosuppression following liver transplantation and the course of inflammatory bowel disease - a case control study.

Mogl MT, Baumgart DC, Fischer A, Pratschke J, Pascher A.

Z Gastroenterol. 2018 Feb;56(2):117-127. doi: 10.1055/s-0043-117183. Epub 2017 Dec 6.

PMID:
29212098
20.

Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease.

Julsgaard M, Kjeldsen J, Bibby BM, Brock B, Baumgart DC.

Gastroenterology. 2018 Feb;154(3):752-754.e1. doi: 10.1053/j.gastro.2017.08.067. Epub 2017 Oct 5. No abstract available.

PMID:
28988916
21.

Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study.

D'Haens G, Vermeire S, Vogelsang H, Allez M, Desreumaux P, Van Gossum A, Sandborn WJ, Baumgart DC, Ransohoff RM, Comer GM, Ahmad A, Cataldi F, Cheng J, Clare R, Gorelick KJ, Kaminski A, Pradhan V, Rivers S, Sikpi MO, Zhang Y, Hassan-Zahraee M, Reinisch W, Stuve O.

J Crohns Colitis. 2018 Jan 24;12(2):188-196. doi: 10.1093/ecco-jcc/jjx128.

22.

Tablet computer enhanced training improves internal medicine exam performance.

Baumgart DC, Wende I, Grittner U.

PLoS One. 2017 Apr 3;12(4):e0172827. doi: 10.1371/journal.pone.0172827. eCollection 2017.

23.

[Fundamentals of the microbiome].

Steinhagen PR, Baumgart DC.

Internist (Berl). 2017 May;58(5):429-434. doi: 10.1007/s00108-017-0224-1. German.

PMID:
28357466
24.

[Microbiome and Gut Inflammation].

Autenrieth DM, Baumgart DC.

Dtsch Med Wochenschr. 2017 Feb;142(4):261-266. doi: 10.1055/s-0042-111608. Epub 2017 Feb 24. Review. German.

PMID:
28235226
25.

Vedolizumab safety in pregnancy and newborn outcomes.

Julsgaard M, Kjeldsen J, Baumgart DC.

Gut. 2017 Oct;66(10):1866-1867. doi: 10.1136/gutjnl-2016-313444. Epub 2017 Jan 10. No abstract available.

PMID:
28073891
26.

Autoimmunity in Crohn's Disease-A Putative Stratification Factor of the Clinical Phenotype.

Roggenbuck D, Reinhold D, Baumgart DC, Schierack P, Conrad K, Laass MW.

Adv Clin Chem. 2016;77:77-101. doi: 10.1016/bs.acc.2016.06.002. Epub 2016 Jun 30. Review.

PMID:
27717419
27.

Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.

Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C.

Aliment Pharmacol Ther. 2016 Dec;44(11-12):1199-1212. doi: 10.1111/apt.13813. Epub 2016 Oct 7.

28.

Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.

Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators.

Lancet. 2016 Sep 24;388(10051):1281-90. doi: 10.1016/S0140-6736(16)31203-X. Epub 2016 Jul 29.

PMID:
27477896
29.

Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study.

Schmidt C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Howaldt S, Stallmach A, Büning C; AEGIS Study Group.

Aliment Pharmacol Ther. 2016 Aug;44(3):259-70. doi: 10.1111/apt.13665. Epub 2016 May 29.

30.

Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study.

Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S; Vedolizumab Germany Consortium.

Aliment Pharmacol Ther. 2016 May;43(10):1090-102. doi: 10.1111/apt.13594. Epub 2016 Apr 1.

31.

Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results.

Dignass A, Akbar A, Hart A, Subramanian S, Bommelaer G, Baumgart DC, Grimaud JC, Cadiot G, Makins R, Hoque S, Bouguen G, Bonaz B.

J Crohns Colitis. 2016 Jul;10(7):812-20. doi: 10.1093/ecco-jcc/jjw032. Epub 2016 Jan 27.

33.

Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.

Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, Diehl L, Eastham Anderson J, Vermeire S, Mansfield JC, Feagan BG, Panes J, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Kirby JA, Irving PM, De Hertogh G, Van Assche GA, Rutgeerts P, O'Byrne S, Hayday A, Keir ME.

Gastroenterology. 2016 Feb;150(2):477-87.e9. doi: 10.1053/j.gastro.2015.10.041. Epub 2015 Oct 30.

34.

Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues.

Schmidt KJ, Müller N, Dignass A, Baumgart DC, Lehnert H, Stange EF, Herrlinger KR, Fellermann K, Büning J.

J Crohns Colitis. 2016 Jan;10(1):31-7. doi: 10.1093/ecco-jcc/jjv175. Epub 2015 Sep 28.

PMID:
26419459
35.

[The human microbiome].

Baumgart DC.

Dtsch Med Wochenschr. 2015 Sep;140(19):1451-6. doi: 10.1055/s-0041-103202. Epub 2015 Aug 25. Review. German.

PMID:
26305138
36.

Tablet computer-based multimedia enhanced medical training improves performance in gastroenterology and endoscopy board style exam compared with traditional medical education.

Baumgart DC, Wende I, Grittner U.

Gut. 2016 Mar;65(3):535-6. doi: 10.1136/gutjnl-2015-309895. Epub 2015 Jun 29. No abstract available.

PMID:
26123026
37.

US-based Real-time Elastography for the Detection of Fibrotic Gut Tissue in Patients with Stricturing Crohn Disease.

Baumgart DC, Müller HP, Grittner U, Metzke D, Fischer A, Guckelberger O, Pascher A, Sack I, Vieth M, Rudolph B.

Radiology. 2015 Jun;275(3):889-99. doi: 10.1148/radiol.14141929. Epub 2015 Feb 6.

PMID:
25668520
38.

Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab.

Krupka N, Baumgart DC.

Drug Des Devel Ther. 2014 Dec 17;9:147-54. doi: 10.2147/DDDT.S50348. eCollection 2015. Review.

39.

Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.

Gasche C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Büning C, Howaldt S, Stallmach A; AEGIS Study Group.

Inflamm Bowel Dis. 2015 Mar;21(3):579-88. doi: 10.1097/MIB.0000000000000314.

40.

Chronic intestinal failure after Crohn disease: when to perform transplantation.

Gerlach UA, Vrakas G, Reddy S, Baumgart DC, Neuhaus P, Friend PJ, Pascher A, Vaidya A.

JAMA Surg. 2014 Oct;149(10):1060-6. doi: 10.1001/jamasurg.2014.1072. Erratum in: JAMA Surg. 2014 Dec;149(12):1313. Baumgar, Daniel C [Corrected to Baumgart, Daniel C].

PMID:
25162284
41.

Myosin IXb variants and their pivotal role in maintaining the intestinal barrier: a study in Crohn's disease.

Prager M, Durmus T, Büttner J, Molnar T, de Jong DJ, Drenth JP, Baumgart DC, Sturm A, Farkas K, Witt H, Büning C.

Scand J Gastroenterol. 2014 Oct;49(10):1191-200. doi: 10.3109/00365521.2014.928903. Epub 2014 Aug 6.

PMID:
25098938
42.

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.

Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Tew GW, Luca D, Tang MT, Diehl L, Eastham-Anderson J, De Hertogh G, Perrier C, Egen JG, Kirby JA, van Assche G, Rutgeerts P.

Lancet. 2014 Jul 26;384(9940):309-18. doi: 10.1016/S0140-6736(14)60661-9. Epub 2014 May 9.

43.

MRI-guided percutaneous transhepatic cholangiodrainage: feasibility study in a porcine model.

Papanikolaou IS, van der Voort IR, Chopra SS, Seebauer CJ, Rump J, Papas MG, Triantafyllou K, Baumgart DC, Teichgräber UK, Wiedenmann B, Rösch T.

Scand J Gastroenterol. 2014 Jun;49(6):722-6. doi: 10.3109/00365521.2014.899619. Epub 2014 Apr 2.

PMID:
24694300
44.

Glucocorticoids regulate barrier function and claudin expression in intestinal epithelial cells via MKP-1.

Fischer A, Gluth M, Weege F, Pape UF, Wiedenmann B, Baumgart DC, Theuring F.

Am J Physiol Gastrointest Liver Physiol. 2014 Feb;306(3):G218-28. doi: 10.1152/ajpgi.00095.2013. Epub 2013 Dec 5.

45.

Acetylsalicylic Acid reduces the severity of dextran sodium sulfate-induced colitis and increases the formation of anti-inflammatory lipid mediators.

Köhnke T, Gomolka B, Bilal S, Zhou X, Sun Y, Rothe M, Baumgart DC, Weylandt KH.

Biomed Res Int. 2013;2013:748160. doi: 10.1155/2013/748160. Epub 2013 Sep 8.

46.

Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines.

Panes J, Bouhnik Y, Reinisch W, Stoker J, Taylor SA, Baumgart DC, Danese S, Halligan S, Marincek B, Matos C, Peyrin-Biroulet L, Rimola J, Rogler G, van Assche G, Ardizzone S, Ba-Ssalamah A, Bali MA, Bellini D, Biancone L, Castiglione F, Ehehalt R, Grassi R, Kucharzik T, Maccioni F, Maconi G, Magro F, Martín-Comín J, Morana G, Pendsé D, Sebastian S, Signore A, Tolan D, Tielbeek JA, Weishaupt D, Wiarda B, Laghi A.

J Crohns Colitis. 2013 Aug;7(7):556-85. doi: 10.1016/j.crohns.2013.02.020. Epub 2013 Apr 11.

47.

Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells.

Fischer A, Gluth M, Pape UF, Wiedenmann B, Theuring F, Baumgart DC.

Am J Physiol Gastrointest Liver Physiol. 2013 Jun 1;304(11):G970-9. doi: 10.1152/ajpgi.00183.2012. Epub 2013 Mar 28.

48.

Increased T-helper 2 cytokines in bile from patients with IgG4-related cholangitis disrupt the tight junction-associated biliary epithelial cell barrier.

Müller T, Beutler C, Picó AH, Otten M, Dürr A, Al-Abadi H, Guckelberger O, Meyer Zum Büschenfelde D, Jöhrens K, Volkmann M, Lankisch T, Voigtländer T, Anders M, Shibolet O, Jefferson DM, Podolsky DK, Fischer A, Veltzke-Schlieker W, Adler A, Baumgart DC, Sturm A, Wiedenmann B, Schott E, Berg T.

Gastroenterology. 2013 May;144(5):1116-28. doi: 10.1053/j.gastro.2013.01.055. Epub 2013 Feb 4.

PMID:
23391819
49.

Risk factors in the development of esophageal adenocarcinoma.

Pohl H, Wrobel K, Bojarski C, Voderholzer W, Sonnenberg A, Rösch T, Baumgart DC.

Am J Gastroenterol. 2013 Feb;108(2):200-7. doi: 10.1038/ajg.2012.387. Epub 2012 Dec 18.

PMID:
23247577
50.

Ulcerative colitis.

Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ.

Lancet. 2012 Nov 3;380(9853):1606-19. doi: 10.1016/S0140-6736(12)60150-0. Epub 2012 Aug 20. Review.

Supplemental Content

Loading ...
Support Center